PSI CRO has announced opening offices in Taiwan, listed as Taiwan PSI Health Development Co. Ltd. at Level 37, TAIPEI 101 TOWER, No. 7, Sec.5, Xinyi Road, Taipei 110, Taiwan.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170920005935/en/
PSI Health Development Co. Ltd. is located at Level 37, TAIPEI 101 TOWER, No. 7, Sec.5, Xinyi Road, Taipei 110, Taiwan (Photo: Business Wire)
“We are excited about the PSI office opening,” says Ava Lu, PSI’s Clinical Operations Manager in Taipei. “We can now bring our staff under the same roof and build a proper PSI home in Taiwan. Our expansion is driven by many clinical trial requests from global sponsors in oncology, infections, IBD (ulcerative colitis, Crohn’s Disease), and other therapeutic areas. We aim to make Taiwan a reliable and consistent contributor to the global clinical trials that PSI manages worldwide. We are keen to keep up with PSI’s unchanging promise of on-time delivery.”
PSI’s expansion into Asia Pacific started in 2017, when PSI opened offices in Sydney, Australia and Seoul, South Korea. PSI is focused on strengthening its global capabilities of delivering clinical trial programs in a variety of therapeutic areas on time and on budget.
“PSI’s global reach in an important differentiator of an agile mid-sized CRO in today’s clinical trial market,” says Katarzyna Skalowska, Global Head of Clinical Operations. “Clinical trials are becoming more complex, while targeting smaller patient populations and requiring a wider geographic spread. PSI is now fully operational on five continents offering robust site relationships with investigators across North America, South America, Africa, Europe, Asia and Australia.”
About PSI CRO:
PSI is a privately-owned, full-service contract research organization (CRO) operating globally. PSI’s reputation in the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover. PSI is committed to being the best CRO in the world as measured by its customers and its employees. In the bi-annual CenterWatch Investigator Surveys of 2015 and 2017, PSI was repeatedly voted Number One Global CRO.
Global headquarters are located in Switzerland at 113a Baarerstrasse, 6300 Zug.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170920005935/en/
Contacts:
Natania Barron
Marketing@psi-cro.com